Madrigal Pharmaceuticals delivered a robust Q2 2025, with Rezdiffra’s performance accelerating and a new U.S. patent extending exclusivity to 2045, materially increasing the long-term revenue horizon.

Madrigal Pharmaceuticals (MDGL) stock gains as the company's Q2 2025 results exceed expectations with a 15-fold surge in ...

Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, ...

Madrigal (MDGL) delivered earnings and revenue surprises of +45.40% and +32.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Jeffrey Epstein’s ex-girlfriend wants to keep grand jury records secret in the sex trafficking case that sent her to prison.

WEST CONSHOHOCKEN, Pa. (AP) — WEST CONSHOHOCKEN, Pa. (AP) — Madrigal Pharmaceuticals Inc. (MDGL) on Tuesday reported a loss of $42.3 million in its second quarter. The West Conshohocken, ...

Convicted sex trafficker Ghislaine Maxwell wants the transcripts of testimony heard by the grand jury that indicted her to ...

It comes as prosecutors in the US urge a court to release some of the records in the sex trafficking case that sent her to ...

Ghislaine Maxwell’s legal maneuvering with Donald Trump took another twist Tuesday, as she begged a federal judge not to ...

Lawyers for Maxwell, a longtime associate of Jeffrey Epstein, in court papers opposed DOJ’s effort to make the materials public.